All News

syringe,needle,vaccine

Vaccine Efficacy in Patients with Seronegative Spondyloarthritis

d Catherine Sims, MD

Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.

Read Article
Flood @FloodRachael et al. ULT reduces non-episodic foot pain in hyperuricaemic patients who fail to meet gout classification criteria. Predicted by double counter or tophus on US. @RheumNow #ACR22 Abstr#1828 https://t.co/iOy0Vo5HVO https://t.co/vF98DFB7hJ

Links:

Richard Conway RichardPAConway ( View Tweet)
McCormick et al Fruit juice and other sugar-sweetened drinks increase gout flare in dose-dependent manner @RheumNow #ACR22 Abstr#1805 https://t.co/aGg5i5XyTK https://t.co/x8ChwASM6P

Links:

Richard Conway RichardPAConway ( View Tweet)
A Novel Treatment Response Measurement Tool for Lupus Dr. Dao discusses abstract 2054 with Dr. Morand at the #ACR22 Convergence. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process. https://t.co/iqqyI953Vz https://t.co/taUjTHsrJ2

Links:

Dr. John Cush RheumNow ( View Tweet)
Even young SLE patients are still at high risk of severe COVID: - in general pop, age is key factor - in SLE, risk is high across age groups (maybe due to both meds & disease) - vaccination makes a big diff but SLE pts still at high risk ABST1591 @CCalabreseDO #ACR22 @RheumNow https://t.co/ra1F79ITn3
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

#ACR22 Abstr#1830 Short attack of arthritis episode is common in Familial Mediterranean Fever. Other pointers? A cohort study in Turkey showed to consider FMF in pts with red mono-oligo arthritis in lower limbs & spondyloarthropathy. 20% were colchicine resistant @RheumNow https://t.co/JXGcgCrhPu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#1839 "Doctor, I have fever & recurrent right-sided tummy pain, is it my appendix?" A case-control study in Turkey reported 16% of unindicated appendectomies prior to FMF diagnosis. This group had late diagnosis and associated with M694V homozygous mutation @RheumNow https://t.co/QtxjuHDXYC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to benefit from TYK2i deucravacitinib @RheumNow #ACR22 Abstr#2133 https://t.co/eVq4XQgX5l https://t.co/HZlTS5OZ2s

Links:

Richard Conway RichardPAConway ( View Tweet)
Mihai et al. Immunosuppressive treatment in SSc assoc lower GI symptom score. @RheumNow #ACR22 Abstr#2174 https://t.co/Y1gyRe8ron https://t.co/tz9cIESzqo

Links:

Richard Conway RichardPAConway ( View Tweet)
Wipfler et al. 1 in 17 individuals prescibed MTX experienced an unexpected barrier in Post-Roe era. @RheumNow #ACR22 Abstr#L09 https://t.co/a8RDZF3JKy https://t.co/cyxJj2adgw

Links:

Richard Conway RichardPAConway ( View Tweet)
Maughan et al inc the late, great, Justin Mason. Treatment cessation in TAK. Feasible in some patients. Initial treatment response, age and Numanotype V arterial involvement predictors. @RheumNow #ACR22 Abstr#L017 https://t.co/5t00prCtFT https://t.co/GGUUNQqyoL

Links:

Richard Conway RichardPAConway ( View Tweet)
Terrier @TerrierBen et al. PNEUMOVAS -pneumococcal vaccination in AAV treated with RTX Double dose of PCV13 at day 0 and day 7 followed by single dose of PPV23 at month 5 significantly improves antibody responses (2 in figure) @RheumNow #ACR22 Abstr#L016 https://t.co/qKqgvv7ZwI https://t.co/UHCuZNSF54

Links:

Richard Conway RichardPAConway ( View Tweet)
I see that despite the condensing of the #ACR22 to 3 days, people are keeping the tradition of leaving at the start of the last day despite it now being a full day. Personally don't think the 3 day meeting has worked, its too packed. @RheumNow

Richard Conway RichardPAConway ( View Tweet)

Promises to be a fantastic session! 🌟Delighted PMR is getting the attention it deserves 🌟 2pm GMT/ 9am EST #ACR22 @RheumNow @SattuiSEMD @EBRheum @drceowen https://t.co/ShRTS1DLXO
Patricia Harkins DrTrishHarkins ( View Tweet)
Wu et al Phase 3 RCT of Telitacicept (targets BlyS and APRIL) in SLE. Primary endpoint met at week 52! SRI(4) 67% vs 33% or 83% vs 38% (P<0.001 for both) depending on how you want to slice it. @RheumNow #ACR22 Abstr#L07 https://t.co/nnKr4AU8Jk https://t.co/9BVF6OljFQ

Links:

Richard Conway RichardPAConway ( View Tweet)
Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on lab values other than increase in trigs. Guess this is why they don't have lab monitoring on label? @RheumNow #ACR22 Abstr#2132 https://t.co/ueIVKQc6jr https://t.co/u99QE71VQ5

Links:

Richard Conway RichardPAConway ( View Tweet)
"Less steroid is more" in multiple diseases. Dr. J Kolfenbach #ACR22 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

van Nieuwland et al. Comparison US/PET/MRI in GCA. Good specificity but relatively low sensitivity for all. PET best for extra-cranial. MRI/US best for isolated cranial. @RheumNow #ACR22 Abstr#1617 https://t.co/CI3TtxOQJL https://t.co/3pJeGo49Gj

Links:

Richard Conway RichardPAConway ( View Tweet)
Stamatis et al. MI in systemic vasculitis vs controls. Only difference - less likely to have pre-existing CVD. No significant difference in outcomes - but this may be due to underpowered - see Figures. @RheumNow #ACR22 Abstr#1615 https://t.co/bYtMr1jGXN https://t.co/QABW2GiVFl

Links:

Richard Conway RichardPAConway ( View Tweet)
×